Besponsa (inotuzumab ozogamicin)

**Product type:** Human Prescription Drug

**Active ingredient:** INOTUZUMAB OZOGAMICIN

**Strength:** .25 mg/mL

**Dosage form:** Injection, Powder, Lyophilized, For Solution

**Route:** Intravenous

**Labeler:** Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

**Marketing category:** BLA (BLA761040)

**Pharmacologic class:** CD22-directed Antibody Interactions [MoA], CD22-directed Immunoconjugate [EPC], Decreased DNA Integrity [PE], Immunoconjugates [CS], Increased Cellular Death [PE]